Clinical trials: Ineffective Erythropoiesis
Congenital Dyserythropoietic Anemia
Registry of Congenital Dyserythropoietic Anemia
Congenital dyserythropoietic anemia is a heterogeneous inherited disease. Hyperplasic erythropoiesis is ineffective and associated with morphological abnormalities of some of the erythroblasts that form the basis of cytological…
- Trial name
- CDA (NCT03983629)
- Testing
- Collection of data and genetic analysis
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Lille Catholic University
β-thalassemia, Ineffective Erythropoiesis
Safety Study for Beta Thalassemia Subjects on PTG-300
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
- Trial name
- TRANSCEND (NCT04054921)
- Testing
- PTG-300
- Where
- 16 sites in United States, Greece and 6 more
- Volunteers
- 34 people
- Sponsor
- Protagonist Therapeutics, Inc.
Ineffective Erythropoiesis
Echinacea-based Supplement Does Not Improve Markers of Performance in Athletes
The purpose of this study was three-fold. We wanted to (1) determine if supplementation with an echinacea-based dietary supplement (ECH) would increase several blood parameters that could affect oxygen carrying capacity in the…
- Trial name
- NCT02134119
- Testing
- Echinacea-based dietary supplement
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Georgia
CDA Type I
Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC
Congenital Dyserythropoietic Anemia Type I (CDAI) is a recessive autosomal disease caused by ineffective erythropoiesis that causes Anemia \& accumulation of iron due to increased absorption of iron in the intestine.
- Trial name
- NCT01795794
- Testing
- omeprazole
- Volunteers
- 12 people
- Sponsor
- Soroka University Medical Center
β-thalassemia, Ineffective Erythropoiesis
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment…
- Conditions
- β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia
- Trial name
- TRANSCEND (NCT03802201)
- Testing
- PTG-300
- Where
- 33 sites in United States, Greece and 7 more
- Volunteers
- 63 people
- Sponsor
- Protagonist Therapeutics, Inc.
Patients With Thalassemia Intermedia,, Congenital Dyserythropoietic Anemia Type I
GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis
Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin…
- Trial name
- GDF 15 (NCT01201135)
- Volunteers
- 80 people
- Sponsor
- Wolfson Medical Center
Beta Thalassemia, Hemoglobinopathy
Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
This 12-month study will evaluate the safety and effectiveness of hydroxyurea in treating beta-thalassemia, a type of anemia caused by defective hemoglobin (the oxygen-carrying pigment in blood).
- Trial name
- NCT00001958
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Congenital Dyserythropoietic Anemia (CDA)
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
Background: Congenital Dyserythropoietic Anemia (CDA) is a group of rare hereditary blood disorders characterized by ineffective erythropoiesis, leading to chronic anemia and organ damage.
- Trial name
- NCT07471516
- Testing
- zoledronic acid
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Inflammation; Muscle, Iron Metabolism
The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and Erythropoiesis
A group of runners received vitamin D (10,000 IU - international unit per day) for two weeks. The aim of the intervention was to check the effect of vitamin D supplementation on selected parameters of inflammation and iron…
- Conditions
- Inflammation; Muscle, Iron Metabolism, Ineffective Erythropoiesis, Healthy
- Trial name
- NCT05880030
- Testing
- Cholecalciferol
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gdansk University of Physical Education and Sport
Congenital Dyserythropoietic Anemia (CDA)
The Congenital Dyserythropoietic Anemia Registry (CDAR)
The investigators have created and maintain a comprehensive registry for patients with the diagnosis of Congenital Dyserythropoietic Anemia (CDA) in North America.
- Trial name
- NCT02964494
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Myelodysplastic Syndrome
The Role of Erythropoietin in Myelodysplastic Syndrome
The purpose of the study is to elucidate the causative molecular events responsible for the abnormal erythropoiesis in MDS.
- Trial name
- NCT00723112
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Utah
Sickle Cell Disease, Thalassaemia
Integrative Diagnosis for SCD and Other RADs
INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
- Conditions
- Sickle Cell Disease, Thalassaemia, Congenital Dyserythropoietic Anemia (CDA), Enzyme Disorder; Anemia
- Trial name
- INTEGRA (NCT07206095)
- Testing
- Analysis of genetic modifiers, Disease phenotyping
- Where
- 9 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute